Skip Navigation

CANCELED - Leukemia as a developmental disorder: Lessons from Down SyndromeHHS Only

Air date: Friday, January 22, 2016, 12:00:00 PM
Time displayed is Eastern Time, Washington DC Local
Description: NCI’s Center for Cancer Research (CCR) Grand Rounds

Dr. Izraeli is a physician scientist that focuses on translational laboratory based research of hemato-oncology with a particular emphasis on childhood leukemia. Another major research interest is centrosomal biology and chromosomal aneuploidy and its roles in developmental biology and cancer. These two interests are merged in the study of leukemias associated with germline aneuploidy (Down Syndrome) and somatic trisomy 21. Several of his discoveries proved to be of general importance to children and adults with acute leukemias. These include the discovery of ERG as an important hematopoietic oncogene and the discoveries of unique activating JAK2 mutations and of mutational activation of the cytokine receptors to TSLP and interleukin 7 in acute lymphoblastic leukemias (ALL). These findings have led to new diagnostic tests and clinical trials of ALL. His more general cancer-aneuploidy and centrosomal biology research has been promoted by he and his colleagues discovery of STIL (previously named SIL), a gene disrupted in T-ALL, as a major centrosomal duplication factor in mammalian cells. He studies how STIL is involved in development and cancer. He has intensive international collaborations in both basic and clinical studies with scientists and clinicians in North America, Australia, Japan and Europe. Dr. Izraeli is the co-chair of the Israeli national study of childhood acute lymphoblastic leukemias, has been the chair of the Biology and Diagnosis committee of the international BFM, the largest international cooperative research group of childhood leukemias and is an elected member of the Board of the European Hematology Association.
Author: Shai Izraeli, M.D., Sheba Medical Center, Tel Hashomer Israel The Dora and Gregorio Shapiro Professor of Hematological Malignancies, Tel Aviv University
Runtime: 1 hour